나노로보틱스 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, nanorobotics market size in 2026 is estimated at USD 10.99 billion, growing from 2025 value of USD 9.92 billion with 2031 projections showing USD 18.37 billion, growing at 10.82% CAGR over 2026-2031.

This report is Segmented by Manufacturing Type (Nanomanipulators, Bio-Nanorobots, and More), Propulsion Method (Magnetic, Chemical, and More), Component (Nanosensors, Control and Communication Modules, and More), Application (Drug Delivery, Medical Imaging and Diagnostics, and More), End-User (Hospitals and Surgical Centers, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Global Nanorobotics Market Trends and Insights

Convergence of MRI-guided magnetic actuation with AI in U.S. and EU hospitals

Hospitals in the United States and Europe now combine real-time MRI imaging with AI-enhanced magnetic steering to guide nanorobots through tortuous blood vessels. Clinical trials report a 2.6-fold gain in hepatic-artery targeting accuracy and 95% algorithm compatibility during liver-cancer treatments. Deployment accelerates because existing MRI suites require no major hardware upgrades, lowering onboarding costs for hospital systems. AI path-planning reduces procedure time and contrast-agent exposure, strengthening the economic case for adoption. The resulting improvement in therapeutic outcomes places this driver at the center of the nanorobotics market growth narrative.

DARPA and EU defense micro-swarm grants accelerating military reconnaissance nanobots

DARPA's latest programs fund swarms of 10,000 programmable micro-robots smaller than a period for navigating denied environments. Parallel EU calls emphasise distributed sensing and autonomous coordination. Early field tests show leader-follower algorithms boosting mission success in maze-like terrains by 40%, but public debate over autonomous lethality is intensifying. While ethical scrutiny could reshape export rules, the funding surge is cementing a pipeline of dual-use technologies transferable to civilian inspection and disaster-relief markets.

Cytotoxicity and immunogenicity concerns limiting FDA / EMA approvals

Regulators grant clearances mainly to passive nanomedicines; active, autonomous nanorobots face tougher scrutiny over long-term biodistribution and organ accumulation. Safety data gaps extend approval timelines and raise developer costs, especially for SMEs lacking the capital to fund exhaustive toxicology studies.

Other drivers and restraints analyzed in the detailed report include:

1. Chinese 14th Five-Year Plan subsidies for nano-manufacturing equipment
2. Rapid drop in DNA-origami synthesis cost enabling mass bio-nanorobot prototyping
3. Ultra-cleanroom infrastructure costs hindering scale-up

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Nanomanipulators captured 31.12% of nanorobotics market share in 2025, anchored in semiconductor metrology lines where atomic-resolution handling is indispensable. Magnetically guided nanobots, aided by MRI compatibility, are forecast to grow at 12.05% CAGR, outpacing the overall nanorobotics market size through 2031.

The mature tooling base of nanomanipulators secures recurring revenue from equipment services, yet magnetically guided platforms attract fresh healthcare budgets, especially for targeted oncology procedures. Hybrid 3D-printed constructs and bacteria-based bots diversify the ecosystem but remain niche owing to higher unit costs and regulatory uncertainties.

Magnetic actuation commanded 41.55% of the nanorobotics market size in 2025 as hospitals leverage existing MRI suites for both imaging and propulsion. Chemical/catalytic systems are projected to post 13.55% CAGR by exploiting in-vivo fuel sources such as urea in bladder-cancer therapy.

Ultrasound-based acoustic propulsion and light-activated mechanisms supply application-specific advantages such as deep-tissue penetration or on-demand activation. The propulsion mix is likely to remain heterogeneous, allowing solution designers to match locomotion physics to use-case constraints.

Complete Report Scope:

• By Manufacturing Type
  • Nanomanipulators
  • Bio-Nanorobots
  • Magnetically Guided Nanobots
  • Bacteria-based Nanobots
  • 3-D Printed Nanorobots
  • Other Manufacturing Types
• By Propulsion / Actuation Method
  • Magnetic Actuation
  • Chemical / Catalytic
  • Acoustic (Ultrasound)
  • Light-Driven
  • Bio-Hybrid / Flagellar
• By Component
  • Nanosensors
  • Nanoactuators and Motors
  • Nanomanipulation Systems
  • Control and Communication Modules
• By Application
  • Drug Delivery
  • Medical Imaging and Diagnostics
  • Minimally-Invasive Surgery and Cell Repair
  • Health-Monitoring Sensors and Replicators
  • Environmental Remediation
  • Precision Electronics and Semiconductor Metrology
  • Military and Reconnaissance
• By End-User
  • Hospitals and Surgical Centers
  • Pharmaceutical and Biotech Companies
  • Academic and Government Research Institutes
  • Semiconductor Foundries
  • Defense Organizations
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • Middle East
      • Saudi Arabia
      • United Arab Emirates
      • Turkey
      • Rest of Middle East
    • Africa
      • South Africa
      • Egypt
      • Rest of Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained 31.65% share in 2025 as DARPA grants and venture funding for CRISPR-nanorobotics kept the region at the innovation frontier. The U.S. nanomedicine segment alone is set to reach USD 279.69 billion by 2033. Canada's research ecosystem complements this strength with gene-editing delivery platforms and oncology-focused prototypes.

Asia-Pacific is the quickest-expanding theatre at 14.46% CAGR, pulled by China's subsidy conveyor and Japan's microscopy precision. Subsidised fabs reduce cost barriers, and regional players demonstrate mosquito-scale drones and high-resolution SEM tools that feed global supply chains. Regulatory regimes lag Western benchmarks but are tightening, especially around medical devices.

Europe balances stringent oversight with generous R&D funding. Projects like NanoRem show how environmental imperatives translate into funded pilots for soil and groundwater cleanup. Germany and the UK dominate precision instrumentation and biotech niches, respectively, while France and Scandinavia advance ethics-focused frameworks that could shape global norms.

1. Bruker Corporation
2. Thermo Fisher Scientific Inc.
3. JEOL Ltd.
4. Oxford Instruments Plc
5. Microbot Medical Inc.
6. Imina Technologies SA
7. EV Group (EVG)
8. Ginkgo Bioworks Inc.
9. Zymergen Inc.
10. Illumina Inc.
11. Nanoics Imaging Ltd.
12. Synthace Ltd.
13. Toronto Nano Instrumentation Inc.
14. Klocke Nanotechnik GmbH
15. Park Systems Corp.
16. Nanosurf AG
17. Nanoscribe GmbH
18. Bruker Alicona
19. Micronit BV
20. DNA Script SA

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study
• 1.3 Research Methodology
• 1.4 Executive Summary

2 MARKET LANDSCAPE

• 2.1 Market Overview
• 2.2 Market Drivers
  • 2.2.1 Convergence of MRI-guided magnetic actuation with AI in U.S. and EU hospitals
  • 2.2.2 DARPA and EU defence micro-swarm grants accelerating military recon nanobots
  • 2.2.3 China's 14th Five-Year Plan subsidies for nano-manufacturing equipment
  • 2.2.4 Rapid drop in DNA-origami synthesis cost enabling mass bio-nanorobot prototyping
  • 2.2.5 Venture funding spike for CRISPR-enabled nanorobotic drug-delivery start-ups
  • 2.2.6 Sub-5-nm semiconductor metrology demand boosting nanomanipulator robotics market
• 2.3 Market Restraints
  • 2.3.1 Cytotoxicity and immunogenicity concerns limiting FDA/EMA approvals
  • 2.3.2 Ultra-cleanroom infrastructure costs hindering scale-up
  • 2.3.3 Absence of sub-100-nm swarm-communication standards
  • 2.3.4 Public ethical backlash to military nano-swarm deployment in Middle-East
• 2.4 Industry Supply-Chain Analysis
• 2.5 Regulatory Outlook
• 2.6 Porter's Five Forces Analysis
  • 2.6.1 Threat of New Entrants
  • 2.6.2 Bargaining Power of Buyers/Consumers
  • 2.6.3 Bargaining Power of Suppliers
  • 2.6.4 Threat of Substitute Products
  • 2.6.5 Intensity of Competitive Rivalry
• 2.7 Technology Snapshot
• 2.8 Impact of Macroeconomic Factors on the Market

3 MARKET SIZE AND GROWTH FORECASTS (VALUE)

• 3.1 By Manufacturing Type
  • 3.1.1 Nanomanipulators
  • 3.1.2 Bio-Nanorobots
  • 3.1.3 Magnetically Guided Nanobots
  • 3.1.4 Bacteria-based Nanobots
  • 3.1.5 3-D Printed Nanorobots
  • 3.1.6 Other Manufacturing Types
• 3.2 By Propulsion / Actuation Method
  • 3.2.1 Magnetic Actuation
  • 3.2.2 Chemical / Catalytic
  • 3.2.3 Acoustic (Ultrasound)
  • 3.2.4 Light-Driven
  • 3.2.5 Bio-Hybrid / Flagellar
• 3.3 By Component
  • 3.3.1 Nanosensors
  • 3.3.2 Nanoactuators and Motors
  • 3.3.3 Nanomanipulation Systems
  • 3.3.4 Control and Communication Modules
• 3.4 By Application
  • 3.4.1 Drug Delivery
  • 3.4.2 Medical Imaging and Diagnostics
  • 3.4.3 Minimally-Invasive Surgery and Cell Repair
  • 3.4.4 Health-Monitoring Sensors and Replicators
  • 3.4.5 Environmental Remediation
  • 3.4.6 Precision Electronics and Semiconductor Metrology
  • 3.4.7 Military and Reconnaissance
• 3.5 By End-User
  • 3.5.1 Hospitals and Surgical Centers
  • 3.5.2 Pharmaceutical and Biotech Companies
  • 3.5.3 Academic and Government Research Institutes
  • 3.5.4 Semiconductor Foundries
  • 3.5.5 Defense Organizations
• 3.6 By Geography
  • 3.6.1 North America
    • 3.6.1.1 United States
    • 3.6.1.2 Canada
    • 3.6.1.3 Mexico
  • 3.6.2 Europe
    • 3.6.2.1 United Kingdom
    • 3.6.2.2 Germany
    • 3.6.2.3 France
    • 3.6.2.4 Italy
    • 3.6.2.5 Rest of Europe
  • 3.6.3 Asia-Pacific
    • 3.6.3.1 China
    • 3.6.3.2 Japan
    • 3.6.3.3 India
    • 3.6.3.4 South Korea
    • 3.6.3.5 Rest of Asia-Pacific
  • 3.6.4 Middle East and Africa
    • 3.6.4.1 Middle East
      • 3.6.4.1.1 Saudi Arabia
      • 3.6.4.1.2 United Arab Emirates
      • 3.6.4.1.3 Turkey
      • 3.6.4.1.4 Rest of Middle East
    • 3.6.4.2 Africa
      • 3.6.4.2.1 South Africa
      • 3.6.4.2.2 Egypt
      • 3.6.4.2.3 Rest of Africa
  • 3.6.5 South America
    • 3.6.5.1 Brazil
    • 3.6.5.2 Argentina
    • 3.6.5.3 Rest of South America

4 COMPETITIVE LANDSCAPE

• 4.1 Market Concentration
• 4.2 Strategic Moves
• 4.3 Market Share Analysis
• 4.4 Company Profiles
  • 4.4.1 Bruker Corporation
  • 4.4.2 Thermo Fisher Scientific Inc.
  • 4.4.3 JEOL Ltd.
  • 4.4.4 Oxford Instruments Plc
  • 4.4.5 Microbot Medical Inc.
  • 4.4.6 Imina Technologies SA
  • 4.4.7 EV Group (EVG)
  • 4.4.8 Ginkgo Bioworks Inc.
  • 4.4.9 Zymergen Inc.
  • 4.4.10 Illumina Inc.
  • 4.4.11 Nanoics Imaging Ltd.
  • 4.4.12 Synthace Ltd.
  • 4.4.13 Toronto Nano Instrumentation Inc.
  • 4.4.14 Klocke Nanotechnik GmbH
  • 4.4.15 Park Systems Corp.
  • 4.4.16 Nanosurf AG
  • 4.4.17 Nanoscribe GmbH
  • 4.4.18 Bruker Alicona
  • 4.4.19 Micronit BV
  • 4.4.20 DNA Script SA

5 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 5.1 White Space and Unmet Need Assessment